143 related articles for article (PubMed ID: 36921580)
21. Integrated bioinformatics analysis of IFITM1 as a prognostic biomarker and investigation of its immunological role in prostate adenocarcinoma.
Qiao S; Zhang W; Su Y; Jiang Y
Front Oncol; 2022; 12():1037535. PubMed ID: 36591519
[TBL] [Abstract][Full Text] [Related]
22. Comprehensive analysis of tumor mutation burden and immune microenvironment in prostate cancer.
Liao J; Ye Y; Xu X
Clin Transl Oncol; 2022 Oct; 24(10):1986-1997. PubMed ID: 35732871
[TBL] [Abstract][Full Text] [Related]
23. Several miRNAs derived from serum extracellular vesicles are potential biomarkers for early diagnosis and progression of Parkinson's disease.
He S; Huang L; Shao C; Nie T; Xia L; Cui B; Lu F; Zhu L; Chen B; Yang Q
Transl Neurodegener; 2021 Jul; 10(1):25. PubMed ID: 34315539
[TBL] [Abstract][Full Text] [Related]
24. Integrative Multiomics Evaluation of IIDH1 Metabolic Enzyme as a Candidate Oncogene That is Correlated with Poor Prognosis and Immune Infiltration in Prostate Adenocarcinoma.
Wen CY; Tsui KH; Chang CH; Chiu YH; Lin SA; Chu CY; Li CJ
J Oncol; 2022; 2022():9854788. PubMed ID: 35132321
[TBL] [Abstract][Full Text] [Related]
25. Prostate adenocarcinoma and COVID-19: The possible impacts of TMPRSS2 expressions in susceptibility to SARS-CoV-2.
Cheng J; Zhou J; Fu S; Fu J; Zhou B; Chen H; Fu J; Wei C
J Cell Mol Med; 2021 Apr; 25(8):4157-4165. PubMed ID: 33609069
[TBL] [Abstract][Full Text] [Related]
26. Special AT-rich Sequence Binding-Protein 1 (SATB1) Correlates with Immune Infiltration in Breast, Head and Neck, and Prostate Cancer.
Ge H; Yan Y; Yan M; Guo L; Mao K
Med Sci Monit; 2020 Jun; 26():e923208. PubMed ID: 32562536
[TBL] [Abstract][Full Text] [Related]
27. The signature of cuproptosis-related immune genes predicts the tumor microenvironment and prognosis of prostate adenocarcinoma.
Yao K; Zhang R; Li L; Liu M; Feng S; Yan H; Zhang Z; Xie D
Front Immunol; 2023; 14():1181370. PubMed ID: 37600770
[TBL] [Abstract][Full Text] [Related]
28. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
29. Studying the system-level involvement of microRNAs in Parkinson's disease.
Chatterjee P; Bhattacharyya M; Bandyopadhyay S; Roy D
PLoS One; 2014; 9(4):e93751. PubMed ID: 24690883
[TBL] [Abstract][Full Text] [Related]
30. Hsa-miR-30a-3p attenuates gastric adenocarcinoma proliferation and metastasis via APBB2.
Zhou K; Cao D; Wang Y; Wang L; Meng X
Aging (Albany NY); 2021 Jun; 13(12):16763-16772. PubMed ID: 34182542
[TBL] [Abstract][Full Text] [Related]
31. The novel transcriptomic signature of angiogenesis predicts clinical outcome, tumor microenvironment and treatment response for prostate adenocarcinoma.
Gu CY; Dai B; Zhu Y; Lin GW; Wang HK; Ye DW; Qin XJ
Mol Med; 2022 Jul; 28(1):78. PubMed ID: 35836112
[TBL] [Abstract][Full Text] [Related]
32. The Construction and Validation of a Novel Ferroptosis-Related Gene Signature in Parkinson's Disease.
Liu T; Wu H; Wei J
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139032
[TBL] [Abstract][Full Text] [Related]
33. Identification and analysis of survival-associated ceRNA triplets in prostate adenocarcinoma.
Li F; Li H; Hou Y
Oncol Lett; 2019 Oct; 18(4):4040-4047. PubMed ID: 31579415
[TBL] [Abstract][Full Text] [Related]
34. Integrated Bioinformatics Analysis for the Screening of Hub Genes and Therapeutic Drugs in Hepatocellular Carcinoma.
Su Q; Li W; Zhang X; Wu R; Zheng K; Zhou T; Dong Y; He Y; Wang D; Ran J
Curr Pharm Biotechnol; 2023; 24(8):1035-1058. PubMed ID: 35762549
[TBL] [Abstract][Full Text] [Related]
35. Unveiling the m6A Methylation Regulator Links between Prostate Cancer and Periodontitis by Transcriptomic Analysis.
Ding D; Liu G; Gao J; Cao M
Dis Markers; 2022; 2022():4030046. PubMed ID: 36133437
[TBL] [Abstract][Full Text] [Related]
36. A compound downregulation of SRRM2 and miR-27a-3p with upregulation of miR-27b-3p in PBMCs of Parkinson's patients is associated with the early stage onset of disease.
Fazeli S; Motovali-Bashi M; Peymani M; Hashemi MS; Etemadifar M; Nasr-Esfahani MH; Ghaedi K
PLoS One; 2020; 15(11):e0240855. PubMed ID: 33171483
[TBL] [Abstract][Full Text] [Related]
37. Modified level of miR-376a is associated with Parkinson's disease.
Baghi M; Rostamian Delavar M; Yadegari E; Peymani M; Pozo D; Hossein Nasr-Esfahani M; Ghaedi K
J Cell Mol Med; 2020 Feb; 24(4):2622-2634. PubMed ID: 31930701
[TBL] [Abstract][Full Text] [Related]
38. Identification of Key Biomarkers and Candidate Molecules in Non-Small-Cell Lung Cancer by Integrated Bioinformatics Analysis.
Yu L; Liang X; Wang J; Ding G; Tang J; Xue J; He X; Ge J; Jin X; Yang Z; Li X; Yao H; Yin H; Liu W; Yin S; Sun B; Sheng J
Genet Res (Camb); 2023; 2023():6782732. PubMed ID: 36688087
[TBL] [Abstract][Full Text] [Related]
39. Long noncoding RNA MIAT regulates TP53 ubiquitination and expedites prostate adenocarcinoma progression by recruiting TBL1X.
Gong Z; Zhang H; Ge Y; Wang P
Biochim Biophys Acta Mol Cell Res; 2023 Oct; 1870(7):119527. PubMed ID: 37356458
[TBL] [Abstract][Full Text] [Related]
40. An androgen receptor-based signature to predict prognosis and identification of ORC1 as a therapeutical target for prostate adenocarcinoma.
Li L; Chen D; Chen X; Zhu J; Bao W; Li C; Miao F; Feng R
PeerJ; 2024; 12():e16850. PubMed ID: 38562999
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
